The journey for an oncology patient often involves a relentless cycle of clinic visits, treatments, and crucially to the work I am involved with, blood draws for diagnosis, monitoring and MRD. This routine, while essential, presents significant burdens – from travel and time off work […]
And Fred said, let there be sequence: and there were sequencers.
Is Roche going to “knock it out of the park” or “jump the shark”? Everyone I know is excited, even if many of them are sceptical, about the Feb 20th webinar and what we will learn about SBX. Alex Dickinson appears to be driving most of the buzz, […]
A new study introduces a sensitive and cost-effective method for MCED and diagnostic using multimodal cfTAPS, enhancing the potential of liquid biopsies. In this post I’ll take a dive into the new paper, lay out a short overview of DNAme-mod methods development, and the possible […]
What does UK Biobank’s Pharma Proteomics election of Olink + Ultima Genomics NGS mean for proteomics researchers, and for the wider genomics community? Does it create a new Olink monopoly on NGS-proteommics? And what’s the impact on NGS technology providers? At the end of last […]
A new company, Tagomics, have a very interesting pre-print: Epigenomic profiling of active regulatory elements by enrichment of unmodified CpG dinucleotides that describes their novel epigenomic profiling approach called “Active-Seq”, a bisulfite-free method designed to enrich unmethylated DNA as opposed to enriching methylated (e.g. MeDIP, GH) or everything […]
NGS would not exist without the important discussions at The Panton Arms where Illumina Next-Generation sequencing was invented…sort of. Professors Sir David Klenerman and Sir Shankar Balasubramanian are being honoured with the 2024 Novo Nordisk Prize for their pioneering work on Solexa sequencing. This led to the $1000 […]
Current liquid biopsy diagnostics, and novel uses such as MRD and Molecular Response analysis, are limited by the amount of ctDNA in a typical patients plasma. ctDNA levels vary across indications (Bettegowda 2014) and generally increase with disease stage. ctDNA is released by tumor cell turnover […]
Apparently you can do Proteomics from Qiagen AllPrep: in In depth profiling of the cancer proteome from the flowthrough of standard RNA-preparation kits for precision oncology, from Mathias Mann’s Proteomics group in Denmark, the authors presents their modifications to Qiagen’s AllPrep (DNA, RNA and protein) […]
Continuing with my summary of what happened at #AGBT23 here’s my round up of the big announcements from Illumina. Of course whilst much of the data presented at the meeting was generated on an Illumina sequencer there was a very significant amount of non-Illumina data […]
